Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
71. |
ECCT/22/03/04 | VIBRI COVID-19-001/2021 A Multi-Centre, Randomized, Double Blind, Phase 2b Trial to Evaluate the Safety and Immunogenicity of Janssen Ad26COVS1 and Novavax NVX-CoV2373 COVID-19 vaccines for Homologous and Heterologous Boosting in Adolescents and Adults Aged 12 to 64 Years with and without HIV infection in 3 African Countries (Kenya, Democratic Republic of Congo, and Rwanda). |
Principal Investigator(s) 1. Dr. Lucas Otieno Tina Site(s) in Kenya Victoria Biomedical Research Institute, |
04-05-2022 |
View |
72. |
ECCT/20/12/03 | CALINA STUDY A multicenter, open-label, single-arm study to evaluate the PK, safety, tolerability and efficacy of a new artemether-lumefantrine (2.5 mg:30 mg) dispersible tablet in the treatment of infants and neonates <5 kg body weight with acute uncomplicated Plasmodium falciparum malaria. Study number: CCOA566B2307 |
Principal Investigator(s) 1. Benhards Ragama Ogutu Site(s) in Kenya KEMRI-Centre for Clinical Research (CCR) |
08-03-2021 |
View |
73. |
ECCT/15/11/04 | VAC040 A Phase 1/2, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety, Tolerability, and Immunogenicity of Stretococcus pneumoniae Whole Cell Vaccine, Inactivated and Adsorbed to Aluminum Hydroxide (PATH-wSP) in Healthy Kenya Young Adults (18 - 40years) and Toddlers (12 - 19months) |
Principal Investigator(s) 1. John Anthony Gerard Scott Site(s) in Kenya KEMRI-Wellcome Trust Research Program |
09-02-2016 |
View |
74. |
ECCT/24/10/06 | A5409 A Phase 2, Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis (RAD-TB) |
Principal Investigator(s) 1. Charity Wambui Kanyoro Site(s) in Kenya 1. KEMRI/WRP CRS (Kericho county) |
18-11-2025 |
View |
75. |
ECCT/24/02/02 | Sabin 003 A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral-Vectored Sudan Ebolavirus Vaccine in Healthy Adults |
Principal Investigator(s) 1. Prof. Videlis Nduba Nzioka Site(s) in Kenya KEMRI / CRDR, KEMRI Clinical Research Annex, Siaya County Referral Hospital Ground. P.O BOX 144-40600 ,Siaya, Kenya |
23-04-2024 |
View |
76. |
ECCT/22/07/01 | GBT021601-021 Study A Phase 2/3 Randomized, Multicenter Study of GBT021601 Administered Orally to Participants with Sickle Cell Disease and an Open-Label Pharmacokinetics Study in Pediatric Participants with Sickle Cell Disease |
Principal Investigator(s) 1. Jessie Nyokabi Githanga 2. Berhnards Ragama Ogutu 3. Videlis Nduba 4. Berhnards Ragama Ogutu Site(s) in Kenya 1. Gertude\'s Children\'s Hospital (Nairobi City county) 2. CENTER FOR RESEARCH IN THERAPEUTIC SCIENCES-STRATHMORE UNIVERSITY MEDICAL CENTER (CREATES (Nairobi City county) 3. / KENYA MEDICAL RESEARCH INSTITUTE- CENTER FOR RESPIRATORY DISEASE RESEARCH(CRDR) (Nairobi City county) 4. KENYA MEDICAL RESEARCH INSTITUTE- SIAYA COUNTY REFERAL HOSPITAL (Siaya county) |
17-10-2022 |
View |
77. |
ECCT/22/09/01 | Agios Study A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease. Mitapivat - AG348-C-020 |
Principal Investigator(s) 1. Bernhards Ragama Ogutu 2. Godfrey Allan Otieno Site(s) in Kenya 1. Strathmore University Medical Centre (Nairobi City county) 2. Victoria Biomedical Research Institute (Kisumu county) 3. KEMRI/CRDR (Nairobi City county) 4. KEMRI Siaya Clinical Research Annex (Siaya county) 5. Gertrude’s Children’s Hospital (Nairobi City county) 6. KEMRI Kondele Children\'s Hospital (Kisumu county) 7. Kombewa Clinical Research Centre (Kisumu county) |
20-12-2022 |
View |
78. |
ECCT/22/10/02 | Agios Study A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease. Mitapivat - AG348-C-020 |
Principal Investigator(s) 1. Janet N Oyieko Site(s) in Kenya 1. Kombewa Clinical Research Centre (Kisumu county) 2. Victoria Biomedical Research Institute (Kisumu county) 3. KEMRI/CRDR (Nairobi City county) 4. KEMRI Siaya Clinical Research Annex (Siaya county) 5. Gertrude’s Children’s Hospital (Nairobi City county) 6. KEMRI Kondele Children\'s Hospital (Kisumu county) 7. Strathmore University Medical Centre (Nairobi City county) |
10-02-2023 |
View |
79. |
ECCT/20/03/01 | GlycoShig3 A Phase 2a age descending study to investigate the safety and immunogenicity of the SF2a-TT15 synthetic carbohydrate-based conjugate vaccine against Shigella flexneri 2a in adult, children and infant target population in endemic countries. |
Principal Investigator(s) 1. Fredrick Kipyegon Sawe Site(s) in Kenya Kenya Medical Research Institute Walter Reed Project Kericho |
23-05-2020 |
View |
80. |
ECCT/23/11/01 | MPZ-MAL-01 A Phase 2a, Multicenter, Open-label, Dose-finding, Dose Escalation Study of Meplazumab in Adult Patients Diagnosed with Uncomplicated Plasmodium falciparum Malaria |
Principal Investigator(s) 1. Lucas Otieno Tina Site(s) in Kenya 1. Victoria Biomedical Research Institute (VIBRI) (Kisumu county) 2. AHERO CLINICAL TRIALS UNIT (Kisumu county) 3. Kenya Medical Research Institute(KEMRI):Siaya Clinical Research Annex (Siaya county) |
20-02-2024 |
View |